Company: ABUS
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001447028-25-000099
Chunk: 5

Company: Arbutus Biopharma Corp
Filing Date: 2025-05-14
Form: 10-Q
Item: Part II, Item 2
Chunk 5
---
 to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.32.2**Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.101The following materials from Arbutus Biopharma Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets; (ii) Condensed Consolidated Statements of Operations; (iii) Condensed Consolidated Statements of Comprehensive Loss; (iv) Condensed Consolidated Statements of Stockholders’ Equity; (v) Condensed Consolidated Statements of Cash Flows; and (vi) Notes to Condensed Consolidated Financial Statements.    104Cover page interactive data file (embedded within the inline XBRL document and included in Exhibit 101).

*    Filed herewith.

**    Furnished herewith.

#    Management Contract or Compensatory Arrangement

+    Certain schedules to this agreement have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy             of any omitted schedules will be furnished supplementally to the SEC upon request. 

38

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on May 14, 2025.

ARBUTUS BIOPHARMA CORPORATION By:/s/ Lindsay Androski  Lindsay Androski  President and Chief Executive Officer(Principal Executive Officer)By:/s/ Tuan NguyenTuan NguyenChief Financial Officer(Principal Financial Officer and Principal Accounting Officer)

39